As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

In a statement to PEOPLE, an Eli Lilly spokesperson said, "FDA’s decision reiterating that the tirzepatide shortage is resolved reflects the tireless work of our manufacturing and quality ...

Following the FDA’s reaffirmation, 503B compounding pharmacies have until March 19 to stop selling compounded tirzepatide. In its motion filed on New Year’s Day, Eli Lilly stated it seeks to ...

Eli Lilly (LLY) stated: “In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs and Border Protection should prevent the illicit ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly's tirzepatide has shown superior efficacy compared to Novo Nordisk's semaglutide (20.2% compared to 13.7% respectively in recent trials). Tirzepatide is offered by Eli Lilly in two ...

That’s how much Eli Lilly ... the tirzepatide story, is going to be about unlocking new categories over and over again.” Beyond revenue growth in diabetes and obesity, Lilly’s strategy ...

We continued to make progress on our manufacturing build-out, and U.S. supply across all doses of tirzepatide was ... FILE PHOTO: An injection pen of Zepbound, Eli Lilly’s weight loss drug ...

Eli Lilly (LLY ... and U.S. supply across all doses of tirzepatide was available throughout Q4," said Lilly CEO David Ricks in a statement. The move in the stock surprised some experts and ...